Imogen R Coe
Overview
Explore the profile of Imogen R Coe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
892
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baskoy S, Khunkhuna A, Scuric B, Naydenova Z, Coe I
Turk J Pharm Sci
. 2024 Jul;
21(3):167-173.
PMID: 38994796
Objectives: Gemcitabine, a first-line chemotherapeutic nucleoside analog drug (NAD) for pancreatic cancer, faces limitations due to drug resistance. Characterizing pancreatic cancer cells' transport characteristics may help identify the mechanisms behind...
2.
Salari A, Appak-Baskoy S, Coe I, Tsai S, Kolios M
RSC Adv
. 2022 May;
11(52):32824-32829.
PMID: 35493567
Adherent cultured cells are widely used biological tools for a variety of biochemical and biotechnology applications, including drug screening and gene expression analysis. One critical step in culturing adherent cells...
3.
Mullin A, Coe I, Gooden E, Tunde-Byass M, Wiley R
Healthc Manage Forum
. 2021 Sep;
34(6):311-315.
PMID: 34535064
An awakening to systemic anti-Black racism, anti-Indigenous racism, and harmful colonial structures in the context of a pandemic has made health inequities and injustices impossible to ignore, and is driving...
4.
Salari A, Appak-Baskoy S, Coe I, Abousawan J, Antonescu C, Tsai S, et al.
Lab Chip
. 2021 Mar;
21(9):1788-1797.
PMID: 33734246
Biological research and many cell-based therapies rely on the successful delivery of cargo materials into cells. Intracellular delivery in an in vitro setting refers to a variety of physical and...
5.
Coe I, Wiley R, Bekker L
Lancet
. 2019 Feb;
393(10171):587-593.
PMID: 30739694
In August 2018, the president of the World Bank noted that "'Human capital'-the potential of individuals-is going to be the most important long-term investment any country can make for its...
6.
Grane-Boladeras N, Williams D, Tarmakova Z, Stevanovic K, Villani L, Mehrabi P, et al.
FASEB J
. 2018 Dec;
33(3):3841-3850.
PMID: 30521377
Equilibrative nucleoside transporters (ENTs) translocate nucleosides and nucleobases across plasma membranes, as well as a variety of anti-cancer, -viral, and -parasite nucleoside analogs. They are also key members of the...
7.
Mariglia J, Momin S, Coe I, Karshafian R
Ultrasonics
. 2018 May;
89:110-117.
PMID: 29775835
Ultrasonically-stimulated microbubbles enhance the therapeutic effects of various chemotherapy drugs. However, the application of ultrasound and microbubbles (USMB) for enhancing the therapeutic effect of nucleoside analogs, which are used as...
8.
Yammine S, Liu C, Jarreau P, Coe I
Science
. 2018 Apr;
360(6385):162-163.
PMID: 29650665
No abstract available.
9.
Grenz A, Bauerle J, Dalton J, Ridyard D, Badulak A, Tak E, et al.
J Clin Invest
. 2017 Jun;
127(6):2438.
PMID: 28569735
No abstract available.
10.
Zafar M, Naydenova Z, Coe I
Nucleosides Nucleotides Nucleic Acids
. 2016 Dec;
35(10-12):631-642.
PMID: 27906634
Human equilibrative nucleoside transporter 1 (hENT1) is a major route of entry of nucleosides and nucleoside analog drugs. The regulation of hENT1 is poorly understood in spite of its clinical...